At Ace Therapeutics, we specialize in preclinical research focusing on glaucoma. Leveraging our expertise in ophthalmology and experimental models, we aim to support fundamental research and preclinical drug development in this field.
Introduction to DBA/2 Mice
The DBA/2 mice, which carry recessive mutations in the genes encoding glycosylated protein nmb (Gpnmb) and tyrosinase-related protein 1 (Tyrp1), serve as a critical tool for glaucoma research. These mice exhibit iris atrophy and pigment deposition in the anterior segment by 3-6 months, with elevated intraocular pressure (IOP) emerging around 8-9 months. This progression leads to optic nerve atrophy and retinal ganglion cell (RGC) degeneration, closely mimicking the pathophysiology of human glaucoma. Additionally, their primary visual cortex (V1) shows a reduced neuron count and impaired visual tuning. This model is essential for understanding the effects of glaucoma on neural function and morphology, thereby facilitating the development of targeted therapeutics.
Fig. 1 Morphological and functional changes in primary visual cortex of glaucoma (DBA/2) mice. (Yang Y, et al., 2024)
Our DBA/2 Mouse Models
Ace Therapeutics has extensive experience in developing preclinical animal models of glaucoma. We will collaborate closely with you to identify the suitable disease model tailored to your specific requirements. Our team of scientists is pleased to offer DBA/2 mouse models, which are well-recognized in the field.
The DBA/2 mouse is a widely used and highly valuable inbred strain that exhibits progressive ocular abnormalities with aging, closely mimicking human hereditary glaucoma.
Ocular pathology: Iris pigment dispersion, iris atrophy, and anterior synechia (adhesion of the iris to the cornea), accompanied by elevated IOP.
Retinal histopathology: Loss of RGCs, GABAergic and cholinergic amacrine cells.
Breeding strategy: Sibling mating.
Our Capabilities
- IOP measurement
Utilizing tonometry techniques, we can accurately measure IOP in live DBA/2 mice, allowing for real-time monitoring of disease progression and treatment efficacy. - Histopathological analysis
Our team performs detailed histological examinations of ocular tissues post-mortem, assessing changes in retinal structure and optic nerve integrity associated with glaucomatous damage. - Visual behavioral analysis
We povide visual behavioral testing services to evaluate visual function and overall health status in DBA/2 mice, providing insights into the impact of glaucoma on quality of life.
Ace Therapeutics collaborates with pharmaceutical companies, biotech firms, and academic institutions. By leveraging our DBA/2 mouse models and customized in vivo studies, we offer robust support for glaucoma research. Partner with us to develop tailored solutions that match your research goals. Ready to start? Contact us now to initiate a discussion about your programs. Let us know how we can help!
References
- Yang Y, et al. Morphological disruption and visual tuning alterations in the primary visual cortex in glaucoma (DBA/2) mice. Neural Regen Res, 2024, 19(1): 220-225.
- Moon J I, et al. Changes in retinal neuronal populations in the DBA/2 mouse. Cell Tissue Res, 2005, 320(1): 51-59.